Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.63), $0.10 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $1.99 million versus the consensus estimate of $1.86 million.

“Our strong performance this quarter reflects Xeris’ dedication to the communities we serve, despite numerous pandemic-related constraints. Prescriptions for Gvoke have continued to rise steadily, illustrating its utility for individuals with diabetes and their families, particularly in the current environment. We've taken thoughtful approaches to maintain continuity and deliver on our mission, including intense preparations for the launch of the Gvoke HypoPen, which was announced just weeks ago, positive results from four of our clinical development programs, and a successful capital raise that strengthens our balance sheet," said Paul R. Edick, Chairman and Chief Executive Officer. "We're very proud of what we've accomplished so far this year, despite the circumstances, and are building on our momentum with the recent Gvoke HypoPen launch that has already accelerated prescription growth, recent and upcoming regulatory dialogue around our clinical programs, and an anticipated European regulatory decision for our ready-to-use glucagon application later this year or early next year."

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.